CRVS Corvus Pharmaceuticals Forecast, Technical & Fundamental Analysis
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function... Show more
CRVS is expected to report earnings to rise 17.27% to -17 cents per share on October 29
Q3'26
Est.
$-0.18
Q1'26
Est.
$-0.15
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.01
Q2'25
Beat
by $0.03
The last earnings report on May 07 showed earnings per share of -15 cents, meeting the estimate of -15 cents. With 513.50K shares outstanding, the current market capitalization sits at 1.27B.
A.I.dvisor indicates that over the last year, CRVS has been closely correlated with ACRS. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRVS jumps, then ACRS could also see price increases.
Momentum Indicator for CRVS turns positive, indicating new upward trend
CRVS saw its Momentum Indicator move above the 0 level on August 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for CRVS just turned positive on August 11, 2026. Looking at past instances where CRVS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
CRVS moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CRVS moved out of overbought territory on July 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CRVS broke above its upper Bollinger Band on August 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRVS entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.653) is normal, around the industry mean (20.281). P/E Ratio (0.000) is within average values for comparable stocks, (25.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.845). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.072).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
